{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:31:30Z","timestamp":1792452690425,"version":"4.5.0"},"reference-count":73,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Inflammatory bowel disease is a chronic, idiopathic and complex condition, which most often manifests itself in the form of ulcerative colitis or Crohn\u2019s disease. Both forms are associated with dysregulation of the mucosal immune system, compromised intestinal epithelial barrier, and dysbiosis of the gut microbiome. It has been observed for a long time that bile acids are involved in inflammatory disorders, and recent studies show their significant physiological role, reaching far beyond being emulsifiers helping in digestion of lipids. Bile acids are also signaling molecules, which act, among other things, on lipid metabolism and immune responses, through several nuclear and membrane receptors in hepatocytes, enterocytes and cells of the immune system. Gut microbiota homeostasis also seems to be affected, directly and indirectly, by bile acid metabolism and signaling. This review summarizes recent advances in the field of bile acid signaling, studies of inflamed gut microbiome, and the therapeutic potential of bile acids in the context of inflammatory bowel disease.<\/jats:p>","DOI":"10.3390\/ijms22169096","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T10:24:17Z","timestamp":1629714257000},"page":"9096","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Bile Acid Signaling in Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0806-6608","authenticated-orcid":false,"given":"Mariusz A.","family":"Bromke","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Immunochemistry, Wroclaw Medical University, Cha\u0142ubi\u0144skiego 10, 50-368 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2753-8092","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Krzystek-Korpacka","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Immunochemistry, Wroclaw Medical University, Cha\u0142ubi\u0144skiego 10, 50-368 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2019.01.002","article-title":"Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data","volume":"156","author":"Coward","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4110\/in.2017.17.1.25","article-title":"Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies","volume":"17","author":"Kim","year":"2017","journal-title":"Immune Netw."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"Seyedian","year":"2019","journal-title":"J. Med. Life"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0002-9343(71)90286-5","article-title":"The enterohepatic circulation of bile salts in gastrointestinal disorders","volume":"51","author":"Garbutt","year":"1971","journal-title":"Am. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/gut.18.9.730","article-title":"Bile acid studies in uncomplicated Crohn\u2019s disease","volume":"18","author":"Vantrappen","year":"1977","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/gut.20.12.1072","article-title":"Bile acid studies in patients with Crohn\u2019s colitis","volume":"20","author":"Rutgeerts","year":"1979","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Andreoli, T., Hoffman, J., Fanestil, D., and Schultz, S. (1986). Mechanisms of bile secretion and hepatic transport. Physiology of Membrane Disorders, Plenum Publishing.","DOI":"10.1007\/978-1-4613-2097-5"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fiorucci, S., and Distrutti, E. (2019). Bile Acid-Activated Receptors: A Review on FXR and Other Nuclear Receptors BT-Bile Acids and Their Receptors, Springer International Publishing.","DOI":"10.1007\/978-3-030-22005-1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/cphy.c120027","article-title":"Bile formation and secretion","volume":"3","author":"Boyer","year":"2013","journal-title":"Compr. Physiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1124\/dmd.114.058065","article-title":"Inflammatory bowel disease alters intestinal bile acid transporter expression","volume":"42","author":"Jahnel","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J. Lipid Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ibd.21403","article-title":"Importance of disrupted intestinal barrier in inflammatory bowel diseases","volume":"17","author":"Salim","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0016-5085(99)70126-5","article-title":"Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis","volume":"116","author":"Schmitz","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1111\/j.1572-0241.1999.01444.x","article-title":"Intestinal permeability test as a predictor of clinical course in Crohn\u2019s disease","volume":"94","author":"Corrao","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejphar.2011.06.058","article-title":"Inhibition of NF-\u03baB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells","volume":"668","author":"Mencarelli","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/hep.27592","article-title":"Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression","volume":"61","author":"Nagahashi","year":"2015","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1021\/jm7015864","article-title":"Novel potent and selective bile acid derivatives as TGR5 agonists: Biological screening, structure-activity relationships, and molecular modeling studies","volume":"51","author":"Sato","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile acid metabolites control TH17 and Treg cell differentiation","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-019-1865-0","article-title":"Microbial bile acid metabolites modulate gut ROR\u03b3+ regulatory T cell homeostasis","volume":"577","author":"Song","year":"2020","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.apsb.2015.01.004","article-title":"Bile acid nuclear receptor FXR and digestive system diseases","volume":"5","author":"Ding","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Renga, B., Mencarelli, A., Cipriani, S., D\u2019Amore, C., Carino, A., Bruno, A., Francisci, D., Zampella, A., Distrutti, E., and Fiorucci, S. (2013). The Bile Acid Sensor FXR Is Required for Immune-Regulatory Activities of TLR-9 in Intestinal Inflammation. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054472"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1038\/ncomms7115","article-title":"Small heterodimer partner interacts with NLRP3 and negatively regulates activation of the NLRP3 inflammasome","volume":"6","author":"Yang","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/ni.2064","article-title":"The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors","volume":"12","author":"Yuk","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10620-020-06715-3","article-title":"Bile Acid Signaling in Inflammatory Bowel Diseases","volume":"66","author":"Fiorucci","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102719","DOI":"10.1016\/j.ebiom.2020.102719","article-title":"Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor","volume":"54","author":"Gadaleta","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for Treatment of Patients with Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2012.09.055","article-title":"The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice","volume":"144","author":"Alemi","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.1700183","article-title":"The Bile Acid Receptor GPBAR1 Regulates the M1\/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis","volume":"199","author":"Biagioli","year":"2017","journal-title":"J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cipriani, S., Mencarelli, A., Chini, M.G., Distrutti, E., Renga, B., Bifulco, G., Baldelli, F., Donini, A., and Fiorucci, S. (2011). The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025637"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hov, J.R., Keitel, V., Laerdahl, J.K., Spomer, L., Ellinghaus, E., Elsharawy, A., Melum, E., Boberg, K.M., Manke, T., and Balschun, T. (2010). Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012403"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Paziewska, A., Habior, A., Rogowska, A., Zych, W., Goryca, K., Karczmarski, J., Dabrowska, M., Ambrozkiewicz, F., Walewska-Zielecka, B., and Krawczyk, M. (2017). A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients. BMC Med. Genom., 10.","DOI":"10.1186\/s12920-016-0239-9"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.immuni.2016.09.008","article-title":"Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome","volume":"45","author":"Guo","year":"2016","journal-title":"Immunity"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hep.31652","article-title":"Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation","volume":"74","author":"Mousa","year":"2020","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/ecco-jcc\/jjaa021","article-title":"A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease with Bile Acid Pathways","volume":"14","author":"Quraishi","year":"2020","journal-title":"J. Crohns. Colitis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/2050640617708953","article-title":"The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease","volume":"6","author":"Torres","year":"2018","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Baumgartner, M., Lang, M., Holley, H., Crepaz, D., Hausmann, B., Pjevac, P., Moser, D., Haller, F., Hof, F., and Beer, A. (2021). Mucosal biofilms are an endoscopic feature of irritable bowel syndrome and ulcerative colitis. Gastroenterology, in press.","DOI":"10.1053\/j.gastro.2021.06.024"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.mayocp.2017.04.010","article-title":"Crohn Disease: Epidemiology, Diagnosis, and Management","volume":"92","author":"Feuerstein","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.53.1.78","article-title":"Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor","volume":"53","author":"Jung","year":"2004","journal-title":"Gut"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41586-020-2047-9","article-title":"Global chemical effects of the microbiome include new bile-acid conjugations","volume":"579","author":"Quinn","year":"2020","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.anaerobe.2016.05.003","article-title":"Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract","volume":"41","author":"Winston","year":"2016","journal-title":"Anaerobe"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12864-016-3152-x","article-title":"Comparative genomics of Clostridium bolteae and Clostridium clostridioforme reveals species-specific genomic properties and numerous putative antibiotic resistance determinants","volume":"17","author":"Dehoux","year":"2016","journal-title":"BMC Genom."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.immuni.2017.11.012","article-title":"The Xenobiotic Transporter Mdr1 Enforces T Cell Homeostasis in the Presence of Intestinal Bile Acids","volume":"47","author":"Cao","year":"2017","journal-title":"Immunity"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41564-018-0306-4","article-title":"Gut microbiome structure and metabolic activity in inflammatory bowel disease","volume":"4","author":"Franzosa","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/3827684","article-title":"Fostering Inflammatory Bowel Disease: Sphingolipid Strategies to Join Forces","volume":"2016","author":"Hadi","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MIB.0000000000000193","article-title":"Bile Acid Malabsorption in Inflammatory Bowel Disease","volume":"21","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_48","first-page":"G906","article-title":"Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation","volume":"294","author":"Raimondi","year":"2008","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/gut.29.6.789","article-title":"Effect of jejunal infusion of bile acids on small bowel transit and fasting jejunal motility in man","volume":"29","author":"Penagini","year":"1988","journal-title":"Gut"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/01.MIB.0000440817.84251.98","article-title":"The Relationship Between Serum Bilirubin and Crohn\u2019s Disease","volume":"20","author":"Lenicek","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.ejim.2011.08.013","article-title":"Bile acid malabsorption investigated by selenium-75-homocholic acid taurine (75SeHCAT) scans: Causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhoea","volume":"22","author":"Borghede","year":"2011","journal-title":"Eur. J. Intern. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.crohns.2014.05.009","article-title":"Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn\u2019s disease: A randomized, double-blind, placebo-controlled study","volume":"8","author":"Beigel","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S470","DOI":"10.1093\/ecco-jcc\/jjy222.824","article-title":"P700 The efficacy of colesevelam to treat bile acid malabsorption in Crohn\u2019s disease: Data from TOPPIC trial","volume":"13","author":"Devarakonda","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Daruich, A., Jaworski, T., Henry, H., Zola, M., Youale, J., Parenti, L., Naud, M.-C., Delaunay, K., Bertrand, M., and Berdugo, M. (2021). Oral Ursodeoxycholic Acid Crosses the Blood Retinal Barrier in Patients with Retinal Detachment and Protects Against Retinal Degeneration in an Ex Vivo Model. Neurother. J. Am. Soc. Exp. Neurother., in press.","DOI":"10.1007\/s13311-021-01009-6"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7453\/gahmj.2014.017","article-title":"The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases","volume":"3","author":"Vang","year":"2014","journal-title":"Glob. Adv. Health Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/003655202760230955","article-title":"Changes in Bile Acid Composition and Effect on Cytolytic Activity of Fecal Water by Ursodeoxycholic Acid Administration: A Placebo-Controlled Cross-over Intervention Trial in Healthy Volunteers","volume":"37","author":"Ek","year":"2002","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_57","first-page":"e14456","article-title":"The secondary bile acids, ursodeoxycholic acid and lithocholic acid, protect against intestinal inflammation by inhibition of epithelial apoptosis","volume":"8","author":"Porru","year":"2020","journal-title":"Physiol. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6\u03b1-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/164_2019_237","article-title":"Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists","volume":"256","author":"Festa","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1124\/mol.110.064501","article-title":"Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist","volume":"78","author":"Rizzo","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Fiorucci, S., and Distrutti, E. (2019). Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders. Bile Acids and Their Receptors, Springer International Publishing.","DOI":"10.1007\/164_2019_227"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e000256","DOI":"10.1136\/bmjgast-2018-000256","article-title":"Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: Proceedings from the 2018 expert panel","volume":"6","author":"Pate","year":"2019","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1053\/j.gastro.2018.12.001","article-title":"Specific Bacteria and Metabolites Associated with Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis","volume":"156","author":"Paramsothy","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_64","first-page":"G310","article-title":"Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection","volume":"306","author":"Weingarden","year":"2013","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/gut.47.3.397","article-title":"Butyrate inhibits inflammatory responses through NFkappaB inhibition: Implications for Crohn\u2019s disease","volume":"47","author":"Segain","year":"2000","journal-title":"Gut"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/ismej.2016.176","article-title":"Faecalibacteriumprausnitzii: From microbiology to diagnostics and prognostics","volume":"11","author":"Duncan","year":"2017","journal-title":"ISME J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/ibd\/izaa262","article-title":"Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity","volume":"27","author":"Fang","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.chom.2017.01.005","article-title":"Microbial Respiration and Formate Oxidation as Metabolic Signatures of Inflammation-Associated Dysbiosis","volume":"21","author":"Hughes","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/gutjnl-2015-309184","article-title":"Structural robustness of the gut mucosal microbiota is associated with Crohn\u2019s disease remission after surgery","volume":"65","author":"Mondot","year":"2016","journal-title":"Gut"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"eaap8914","DOI":"10.1126\/scitranslmed.aap8914","article-title":"Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome","volume":"10","author":"Vila","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1073\/pnas.0804812105","article-title":"Faecalibacteriumprausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients","volume":"105","author":"Sokol","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s12328-020-01296-0","article-title":"Successful response of primary sclerosing cholangitis and associated ulcerative colitis to oral vancomycin may depend on brand and personalized dose: Report in an adolescent","volume":"14","author":"Buness","year":"2021","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/CEG.S186097","article-title":"A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis","volume":"12","author":"Vaughn","year":"2019","journal-title":"Clin. Exp. Gastroenterol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/9096\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:50:00Z","timestamp":1760165400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/9096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":73,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ijms22169096"],"URL":"https:\/\/doi.org\/10.3390\/ijms22169096","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]}}}